Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas.

@article{Matsuyama2011ProteasomalNS,
  title={Proteasomal non-catalytic subunit PSMD2 as a potential therapeutic target in association with various clinicopathologic features in lung adenocarcinomas.},
  author={Yasushi Matsuyama and Motoshi Suzuki and Chinatsu Arima and Qin Miao Huang and Shuta Tomida and Toshiyuki Takeuchi and Ryoji Sugiyama and Yasutomo Itoh and Yasushi Yatabe and Hidemi Goto and Takashi Takahashi},
  journal={Molecular carcinogenesis},
  year={2011},
  volume={50 4},
  pages={301-9}
}
We previously identified PSMD2, a subunit of the 19S regulatory complex of proteasomes, as a constituent of a signature associated with the acquisition of metastatic phenotype and poor prognosis in lung cancers. In the present study, we found that knockdown of PSMD2 decreased proteasome activity, and induced growth inhibition and apoptosis in lung cancer cell lines. These effects of siRNA-mediated PSMD2 inhibition were associated with changes in the balance between phosphorylated AKT and p38… CONTINUE READING